Tubular hypertrophy due to work load induced by furosemide is associated with increases of IGF-1 and IGFBP-1  by Kobayashi, Shuzo et al.
Kidney International, Vol. 47 (1995), PP. 818—828
Tubular hypertrophy due to work load induced by furosemide is
associated with increases of IGF-1 and IGFBP-1
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Tubular hypertrophy due to work load induced by furosemide is
associated with increases of IGF-1 and IGFBP-1. We have examined the
expression of insulin-like growth factor 1 (IGF-1), IGF binding protein-i
(IGFBP-1), and IGF binding protein-3 (IGFBP-3) in the rat distal
nephron during increased cell work load and hypertrophy, induced by the
diuretic, furosemide. Furosemide was given for six days to increase distal
sodium delivery and uptake. To mitigate salt loss, the animals drank 0.8%
NaCl and 0.1% KCI. Control rats were infused with vehicle (0.9% saline)
and drank tap water. Furosemide increased urinaly volume (13-fold) and
sodium excretion (eightfold), and decreased urine osmolarity (fourfold).
By immunocytochemistry, staining for IGF-1 and IGFBP-i was markedly
increased in distal convoluted tubules and cortical collecting ducts; both
segments also underwent hypertrophy. Increased staining for the peptides
was evident early (1 hr, 18 hr) after furosemide, prior to hypertrophy of
cells. Whereas transcripts of IGF-1 and IGFBP-3 mRNA showed little or
no increase in extracts from furosemide-treated kidney cortices, IGFBP-1
mRNA was increased threefold 18 hours after furosemide. Alterations of
IGF-1 and IGFBP-1 were independent of changes in plasma aldosterone,
glucocorticoids or arginine vasopressin. That IGFBP-1 mRNA increased
threefold without significant changes in IGF-1 mRNA suggests that
hypertrophic stimuli might initially induce the synthesis of IGF binding
protein followed by the trapping of extracellular IGF-1. The present study
raises the possibility of IGF-1 and IGFBP-1 being involved in processes
that lead to tubular hypertrophy. IGFBP-1 may regulate these effects by
binding to and interaction with IGF-1.
When renal mass is reduced, whether by surgical ablation or
disease, the remaining kidney tissue increases in size and function.
Compensatory renal growth (CRG), occurs mainly by hypertro-
phy rather than hyperplasia. The hypertrophy is accompanied by
increase of the fractional excretion of water, sodium, potassium,
and bicarbonate, in association with single-nephron hyperperfu-
sion, hypertension and hyperfiltration [1—41. The mechanisms
which lead to cellular hypertrophy are poorly understood and
need to be defined. One hypothesis ascribes CRG to increased
work load. Following renal ablation, the remaining kidney reab-
sorbs more sodium and excretes more potassium. The major sink
for energy consumption in the kidney is the active reabsorption of
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sodium [5]. It has been suggested that increase of sodium trans-
port provides the stimulus for cell growth [6, 7]. Stimulation of the
Na/H antiport is an early event during hypertrophy of renal
proximal tubular cells [8]. It leads to augmented activity of the
sodium pump, increase in the number of pump units, amplifica-
tion of the basolateral membrane and enlargement of cell size [9].
On the other hand, other experiments have suggested that
increased tubular reabsorption is in itself an insufficient stimulus
for CRG. Ureteral diversion in association with nephrectomy
prevents CRG but not increased glomerular filtration and tubular
reabsorption [10].
Insulin-like growth factor-i (IGF-1) is a 7.6 kDa, cationic (p1
8.5) polypeptide (70 amino acids) that promotes diverse biological
activities, including cell proliferation, morphogenesis and differ-
entiation [11, 12]. It also participates in regeneration of injured or
ischemic tissue [13]. IGF-1 is made by many tissues including the
kidney and may exert its function in an autocrine and/or paracrine
fashion [14—16]. There is evidence that IGF-1 increases renal
plasma flow and GFR in rats [17] and that it could be involved in
compensatory hypertrophy, as tissue IGF-i or immunostainable
IGF-1 is increased in uninephrectomized rat kidney [18—20].
However, little is known regarding any role that the peptide may
play in hypertrophy at the cellular level.
The IGF-binding proteins (IGFBPs) are important modulators
of the biological actions of IGF-1 and IGF-2. It is known that
there are at least six forms of IGFBPs: one is a growth hormone
(GH)-dependent large molecular form (150 kDa) of IGFBP
(IGFBP-3), and the others are GH-independent small molecular
forms (24 to 40 kDa) of IGFBPs (IGFBP-1, 2, 4, 5, 6) [21].
IGFBPs, particularly low molecular weight forms present in
extracellular fluids, seem to modulate the action of IGF-1 [22].
We have reported recently that a low molecular weight form of
IGFBP (IGFBP-1, 25 kDa) is colocalized with IGF-1 in cells of
the distal nephron in rat kidney [23]. Increased work load, alone,
can stimulate cell hypertrophy in many settings where tissue is not
lost by removal or disease. We show now that treatment with
furosemide, a diuretic which induces cell hypertrophy in associa-
tion with enhanced sodium delivery and reabsorption in the distal
nephron [6, 7], also results in increased immunostainable IGF-1
and IGFBP-1 in the same segments mainly through increased
local synthesis of IGFBP-1 as evidenced by selective increase of
IGFBP-1 mRNA.
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Methods
Forty male Fischer 344 rats, weighing approximately 200 to
250 g, were used. These rats had free access to standard laboratoty
chow and tap water prior to the experiment. During experiments,
furosemide was administered to rats for six days consecutively.
Experimental designs used here were similar to those described
by Kaissling and Stanton [6, 71. The rats in this experiment were
given either furosemide (12 mg/day/rat, Diamazon, Hoechst-
Roussel, Germany) or vehicle (0.9% NaC1) subcutaneously for six
days via osmotic minipump (2ML1, Alza, Palo Alto, CA, USA)
inserted into the neck. Each pump had a capacity of 2 ml, with a
delivery rate of 10 p1/hr. To determine whether the effect of
furosemide on kidney IGF-I resulted from secondary alterations
in adrenal corticosteroid levels, rather than from increased so-
dium delivery to the distal nephron, rats were adrenalectomized
and given aldosterone (0.5 g/100 g/day) and dexamethasone (1.2
g/100 g/day) using osmotic minipump (2002, AIza). The capacity
of this pump was 200 1d, with a delivery rate of 0.4 p1/hr. It is
known that this protocol keeps these hormones at physiologically
relevant levels [24]. Also, to control for the increased vasopres-
sin levels which are known to follow diuresis, arginine vaso-
pressin (AVP), 3000 ng/day, was administered by a third osmotic
minipump. This dose has been shown to increase AVP levels by
more than 15-fold [25]. These groups are summarized below.
(1) Saline (N = 4). Saline-treated adrenal intact rats.
(2) Furosemide (N = 4). Furosemide-treated adrenal intact rats.
(3) ADX+saline (N = 5). Saline-treated adrenalectomized rats,
replaced with aldosterone and dexamethasone.
(4) ADX+furosemide (N = 5). Furosemide-treated adrenalec-
tomized rats, replaced with aldosterone and dexamethasone.
(5) ADX+AVP+saline (N = 5). Saline- and AVP-treated
adrenalectomized rats, replaced with aldosterone and dexameth-
asone.
(6) ADX+AVP+furosemide (N = 5). Furosemide- and AVP-
treated adrenalectomized rats, replaced with aldosterone and
dexamethasone.
(7) High aldosterone (N = 3). High dose of aldosterone (2mg/i 00
g/day) for 18 hours given in saline-treated, adrenal intact rats.
Rats were anesthetized with brevital sodium (50 mg/kg, Eli
Lilly, IN, USA), adrenalectomized, and implanted with osmotic
minipumps to replace aldosterone, dexamethasone and AVP.
These rats were housed individually in a metabolic cage. One
week after adrenalectomy, another minipump was implanted to
infuse furosemide or vehicle; xylocaine (Astra, MA, USA) was
used for local anesthesia. Twenty-four hours after implantation of
the minipump, urine collection (24-hr/day, 3 consecutive days)
was initiated for analysis of urine volume, sodium and potassium
excretion. Furosemide-treated rats were given 0.8% NaC1 and
0.1% KC1 as drinking solution; saline-treated rats were given tap
water. Six days after furosemide or vehicle treatment, perfusion
fixation was performed as described below and blood was col-
lected from the abdominal aorta to measure plasma sodium,
potassium concentration and hematocrit.
Rats were also studied 18 hours or 1 hour after a single
injection of furosemide (20 mg/kg, i.p.), or vehicle (0.5 ml saline,
i.p.). For the 18 hour study, furosemide treated rats were given
0.8% NaCI and 0.1% KC1 as drinking solution. For the one hour
study, venous catheters were placed in pentobarbital anesthetized,
tracheostomized rats. After 60 minutes of equilibration with
infusion (20 gl/min) of Krebs-Ringer buffer (KRB), furosemide or
vehicle was given, and KRB infusion continued at rates adjusted
for urine volumes, measured through a catheter in the urinary
bladder.
Perfusion fixation
Upon anesthesia with sodium pentobarbital, a mid abdominal
incision was made, and kidneys were fixed by perfusion with 4%
paraformaldehyde in 0.1 M phosphate buffer as we have described
previously [23]. The kidney was removed and a coronal section,
cut 3 mm in thickness through the midportion of the kidney, was
immersed with the same fixatives for one to two hours. The tissue,
after being washed with PBS, was processed rapidly into paraffin
for embedding (within 2 hr). Three j.tm-thick sections on slides
coated with chrome-alum gelatin were used for immunohisto-
chemistry.
Electron microscopic observations
Kidneys were rinsed via an aortic canula for 20 seconds with
20 m phosphate buffered saline and fixed for three minutes by
perfusion with 2% glutaraldehyde in 0.1 M Na cacodylate buffer
pH 7.4. After perfusion, the kidney tissues, incised to about
1 mm3, were further immersed in the same fixatives followed by
1% osmium tetroxide in water. After embedding in epoxy resin,
one micron semithin sections were stained with 1% toluidine blue
in 1% borax solution. Ultrathin sections were stained with uranyl-
acetate and lead citrate and observed with a JEOL-100 CX
electron microscope (JEOL, Tokyo, Japan).
Immunohistochemisti'y
Immunohistochemistry was performed by the avidin-biotin-
peroxidase technique [26]. Deparaffinized and rehydrated slides
were immersed with 3% aqueous hydrogen peroxide for 30
minutes to quench endogenous peroxidase activity. Then, to
reduce non-specific binding of biotinylated goat anti-rabbit anti-
body, they were placed in 3% normal goat serum in 0.1 M
Tris-buffered saline containing 0.05% Tween 20 (TBS-T) and
0.05% sodium azide. Sections were incubated with the following
antibody for two hours at 37°C in a humidified chamber: (1) rabbit
anti-human IGF-I antibody (provided through the National Insti-
tute of Diabetes, Digestive and Kidney Disease, National Hor-
mone and Pituitary Program by Drs. Louis E., Underwood and
Judson J., Van Wyk, University of North Carolina, Chapel Hill,
NC, USA), diluted 1:400 in TBS-T; (2) rabbit antibody raised
against the 25 kDa IGFBP-1 purified from human amniotic fluid
[27], diluted 1:1200 in TBS-T. Following three rinses in TBS-T, a
biotinylated goat anti-rabbit antibody (Vector Laboratories, Bur-
lingame, CA, USA), diluted 1:500 in TBS-T, was applied for 30
minutes. Subsequently, the sections rinsed in TBS-T were incu-
bated in avidin-biotin peroxidase complex (ABC Elite; Vector
Laboratories) for 30 minutes. Finally, the color was developed by
treating the sections with a chromogenic component composed
of 0.05% 3, 3'-diaminobenzidine (DAB) (Sigma Chemical Co.,
Poole, Dorest, UK), 0.01% (vol/vol) hydrogen peroxide and
0.01 M imidazol made in 0.1 M Tris-HC1 buffer (pH 7.4). Tissue
sections were lightly counterstained with hematoxylin, dehydrated
in an ascending ethanol series and xylene, and mounted with
coverslips.
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Table 1. Water intake and urinary findings in chronic experiment
Water intake uVol uNa uK uOsm
mOsmlkgGroup mi/day mEq/day
Saline N = 4 13.6 2.7 4.8 0.7 1.09 0.28 2.12 0.07 2184 80
Furosemide N = 4 69.3 12.1° 63.7 7.6a 9.2 0.4° 2.47 0.47 531 32°
ADX + saline N 5 10.4 2.3 5.1 0.5 0.91 0.12 2.02 0.14 2323 133
ADX + furosemide N 5 60.8 14.0" 59• 134b 8.61 1.92" 2.97 0.6" 538 63b
ADX + AVP + saline N = 5 13.4 3.0 4.7 1.3 1.03 0.28 2.53 0.47 2587 80
ADX + AVP + furosemide N = 5 53.6 16.6" 48.7 11.2c 6.8 1.23° 2.87 0.51 601 67°
Values are means SD. N is the number of rats.
a P < 0.05, vs. saline-treated group
bP < 0.05, vs. ADX + saline-treated group
P < 0.05, vs. ADX + AVP + saline-treated group
Table 2. Plasma electrolytes, osmolality and hematocrit, and change of body weight in chronic experiment
Body wt Plasma
Group Before After Na K Osm Hct
Saline N = 4 220 8 228 5 142.8 4 3.96 0.55 291 8 46 1.8
Furosemide N = 4 222 7 219 6 143.1 2 3.39 0.31 292 4 45.3 1.3
ADX + salineN= 5 225±7 224±11 144.6±2.7 3.52±0.19 288±8 43.6±2.7
ADX + furosemide N = 5 216 13 209 25 140.9 8.2 3.29 0.21 290 9 46.4 4.4
ADX +AVP + salineN 5 234±7 231±9 145.5±2.3 3.51 292±8 43.4±2.6
ADX + AVP furosemide N = 5 227 8 218 18 143 4.3 3.07 0.63 289 9 44.8 1.9
High aldosterone (for 18 hr) N = 3 265 8 268 6 143.7 0.8 2.85 0.3° 288 3 41.7 0.6
Values are means SD. N is the number of rats.
aP < 0.05 vs. saline-treated group
Immunospecificity study
The specificity of staining for IGF-1 or IGFBP-1 was verified in
several ways. Sections were treated in similar manner, except as
described: (1) nonimmune rabbit serum or lgG (10 tg/m1) was
used instead of specific primary antibody; (2) biotinylated anti-
body was omitted. To further evaluate immunospecificity, anti-
body preabsorbed with an excess antigen was applied. Briefly, 300
1.d of IGF-1 (5 M) or IGFBP-1 (67 nM) was blotted onto the
nitrocellulose paper, and dried at room temperature. These
papers were washed and immersed with TBS-T containing 1%
ovalbumin overnight at 4°C. Then, the respective antibody, di-
luted in the same titer as is used in immunohistochemistry, was
added to the nitrocellulose paper saturated with antigen, and
incubated for one hour at 37°C with continuous agitation. The
first preabsorbed antibody solution was collected through glass
fiber filter, and a portion of this solution saved. After the
nitrocellulose paper was washed with TBS-T, 0.2 M glycine buffer
containing 0.1% Tween 20 and 3% crystalline bovine serum
albumin (pH 2.8) was added. Following the elution of antibody
from the nitrocellulose paper, the paper was again incubated with
the remaining first preabsorbed antibody. The procedures de-
scribed above were repeated three times.
mRNA analysis
Total cellular RNA was extracted from control kidney cortices
and from cortices treated with furosemide (20 mg/kg, i.v.) for 1 or
18 hours [28]. The integrity of each sample was verified by
electrophoresis on an agarose/formaldehyde gel, and its quantity
was determined spectrophotometrically. Polyadenylated RNA
was separated by chromatography on oligo-dt-cellulose columns.
Rat IGF-1 cDNA insert was excised from a clone provided by Dr.
Graeme Bell of the University of Chicago and was subcloned in
the plasmid pGEM-3Z. Rat IGFBP-1 and IGFBP-3 cDNA were
provided by Dr. Joseph D'Ercole, (Department of Pediatrics,
University of North Carolina, Chapel Hill, NC, USA). Since
Northern blot analysis described below failed to show a clear
visible transcript of IGF-i mRNA in control kidney cortices,
solution hybridization nuclease protection assay was performed
for the IGF-1 mRNA analysis according to the method described
by Zinn, Dimaio and Maniatis [29]. The antisense cRNA tran-
script obtained by T7 RNA polymerase was used for the RNAase
protection assay. The poly(A) containing RNA samples (2 jLg)
were mixed with 2 x 106 CPM freshly synthesized antisense
cRNA in a 20 j.d hybridization mixture containing 80% form-
amide. After denaturation and annealing, the RNA-RNA hybrids
were digested with RNAase-A (40 .tglml) and RNAase Ti (2
g/ml) at 37°C for 60 minutes. After proteinase-K digestion and
phenol-chloroform extraction, the undigested hybrids were recov-
ered by ethanol precipitation. The denatured hybrids were sepa-
rated on a 5% sequencing gel and autoradiographed on Kodak
AR-5 X-ray film. In experiments, yeast tRNA was included as a
negative control and liver RNA as a positive control. For IGFBPs
mRNA analysis in kidney cortices, Northern blots were success-
fully performed. Poly(A) RNA (15 g) was denatured by
incubation at 60° for 20 minutes in gel-running buffer (0.04 M
morpholinopropanesulfonic acid, 10 m sodium acetate, and
0.5 mM EDTA, pH 7.5) with 50% formamide and 6% formalde-
hyde and electrophresed in a 1% agarose gel containing 6%
formaldehyde. After RNA transfer from the gel to nitrocellulose
paper, the paper was baked at 80°C and prehybridized and
hybridized with [32P] IGFBP-i or IGFBP-3 eDNA for 24 hours at
42°C. The paper was washed three times at room temperature for
10 minutes with 2x SSC and 0.1% SDS, followed by three
consecutive washes at room temperature, 42 and 65°C in 0.1 x
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Fig. 1. Toluidine blue stained semithin section,
(A) control, (B) after 6 days of Jhrosemide
treatment. Distal nephron segments (asterisks)
show marked hypertrophy in the furosemide
treated rat (B). Magnification, X480.
SSC and 0.1% SDS for one hour, and then autoradiographed. A
rat f3-actin cDNA was used as an internal control. RNA abun-
dance was calculated using scanning laser densitometry with the
integrated area. All experiments were performed in duplicate or
triplicate.
Statistics
All data are expressed as mean SD. For multiple comparisons,
one way analysis of variance followed by Student-Newman-Keuls
test was performed. Paired t-test was used for the comparison at
a different period in each group. P values less than 0.05 were
considered statistically significant.
Results
Functional studies
As shown in Tables 1 and 2, furosemide treatment increased
urine volume dramatically in parallel with increase in drinking
throughout the experiment. During this period, animals had no
severe diarrhea although a few animals, especially furosemide-
and vasopressin-treated adrenalectomized animals, lost body
weight, probably due to the stress resulting from implantation of
three minipumps (Table 2). In adrenal-intact animals, furosemide
increased urine volume from 4.8 0.7 to 63.7 7.6 ml/day (P <
0.05); urinary excretion of sodium from 1.09 0.28 to 9.2 0.4
mEq/day (P < 0.05), and decreased urine osmolarity from 2184±
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Fig. 2. Electron micrographs of distal convoluted
tubule cell, (A) control, (B) after 6 days of
furosemide treatment. Note marked hypertrophy
and increase in mitochondrial profiles and
basolateral membrane profiles in a principal
cell. Magnification, X6,000.
80 to 531 32 mOsm/kg H20 (P < 0.05). The furosemide-treated
animals drank 69.3 12.1 ml, whereas control animals drank
13.6 2.7 ml. There was a trend towards increase of urinary
potassium excretion, but this did not reach statistical significance
(2.12 0.07 in controls vs. 2.47 0.47 mEq/day in furosemide;
Table 1). There was a corresponding trend for decrease of plasma
potassium concentration, but this was also not significant (3.96
0.55 in controls vs. 3.39 0.31 mEq/liter in furosemide; Table 2).
In ADX rats, furosemide treatment produced a similar effect.
Thus, urinary excretion of fluid and sodium was increased, and
urine osmolarity was decreased. Urinary potassium excretion was
increased in ADX plus furosemide-treated animals compared
with that in ADX plus vehicle-treated animals. In AVP-treated
and adrenalectomized rats, furosemide also induced a dramatic
diuresis in association with the increase in urinary sodium excre-
tion, although the response of diuresis and natriuresis was
blunted. There was no statistical difference in potassium excretion
between ADX- and AVP-treated furosemide animals, and ADX-
and AVP-treated vehicle controls. Although there was a trend for
body weight to be reduced (227 8 vs. 218 18 g), this was not
statistically significant.
Morphology
Toluidine blue stained semithin sections from chronic furo-
semide treated rats showed marked hypertrophy of the distal
convoluted tubules (DCT), connecting tubules (CNT) and cortical
collecting ducts (CCD). (These nephron segments are hereafter
collectively referred to as "distal segments beyond the macula
densa.") The degree of hypertrophy was of large magnitude, such
that morphometric analysis was not necessary (Fig. 1). These
results are comparable to those of Kaissling and Stanton [6].
Electron microscopic observations also demonstrated marked
hypertrophy in DCT cells, CNT cells and principal cells (Fig. 2).
Particularly, there was a large increase in basolateral membrane
profiles.
.1.
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Fig. 2. Continued.
Immunohistochemistty
As we have reported before, preabsorption of antibody with
excess antigen or the use of non-immune rabbit serum resulted in
the abolition of specific, immunohistochemical staining for IGF-1
and IGFBP-1. Also, a cross absorption study showed that the
staining was unique for the relative specific antibody [231. As the
staining pattern of IGF-1 and IGFBP-1 was identical, the descrip-
tion refers to both IGF-1 and IGFBP-1.
In saline-treated control animals, the most intense staining was
in the papillary collecting ducts (PCD) (not shown) as we have
reported before for untreated controls [23]. The staining de-
creased in intensity towards the outer medulla. There was mod-
erate staining in the cortical collecting duct (CCD) (Fig. 3 A, C)
and medullary thick ascending limb (mTAL). The cortical collect-
ing duct showed positive immunostaining only in principal cells.
This finding was more clear in araldite-embedded semithin sec-
tions, as previously reported [23]. There was modest staining in
distal convoluted tubules (DCT; Fig. 3 A and C), and in thin limbs
of Henle's loop (THL, not shown). The macula densa, however,
lacked immunoreactivity. There was no immunostaining in gb-
meruli. Proximal tubules (PT), revealed little staining (Fig. 3 A,
C). In furosemide-treated rats, there was marked increase in the
density of immunostainable IGF-1 in the distal segments beyond
the macula densa (Fig. 3B). Concomitantly, there was increased
staining for IGFBP-1 (Fig. 3D). It could not be determined with
certainty whether or not the staining intensity in PCD was
increased, as a strong immunoreactivity existed even in normal
control rats. We studied whether the increase of immunostainable
IGF-1 in the distal segments beyond the macula densa of
furosemide-treated animals resulted from secondary alterations
of adrenal corticosteroid or AVP levels, rather than directly from
increased sodium delivery to the distal nephron. For this purpose,
rats were adrenalectomized and given replacement doses of
aldosterone and dexamethasone with or without vasopressin.
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Fig. 4. Solution hybridization nuclease protection assay for IGF-ImRNA. There is modest increase of IGF-1 mRNA in 18 hour furosemide-treated kidney
cortices by 1.4-fold. Lane 1: Undigested probe. Lanes 2 and 3: control kidney (without furosemide). Lanes 4 and 5: furosemide-treated (20 mg/kg) rats
1 hr after injection. Lanes 6 and 7: furosemide-treated (20 mg/kg) rats 18 hr after injection. Lane 8: tRNA (negative control). Lanes 9 to 12: normal
rat livers poly A RNA (positive control); Lane 9: 10 jig; Lane 10, 5 g; Lane 11, 2.5 g; Lane 12, 1.25 g.
As reported previously [6], furosemide treatment, regardless of
ADX and corticoid hormones with or without AVP, induced
hypertrophy of the superficial distal nephron. ADX, corticoids
and AVP by themselves were ineffective. Likewise, increased
IGF-1 and IGFBP-1 immunoreactivity were seen in the distal
segments beyond the macula densa only of rats which received
furosemide regardless of ADX, corticoids and AVP. Aldosterone
alone reduced plasma potassium levels, but did not affect IGF-1
or IGFBP-l staining.
Increased immunostaining for IGF-1 and IGFBP-1 was also
present at 18 hours and 1 hour following administration of
furosemide (data not shown).
IGF-1 and IGFBPs mRNA
As determined by solution hybridization nuclease protection
assay, single bands of protected transcripts for 1GF-1 were visible.
There was a modest increase of IGF-1 mRNA by 1.2-fold and 1.4-
fold in one hour furosemide-treated, and 18 hour furosemide-
treated kidney cortices, respectively (Fig. 4). In view of the margin
of error for the assay, this change could not be considered
significant. In control kidney cortices, there were enough tran-
scripts of IGFBP-1 and IGFBP-3 so that Northern blots were
sufficient to detect them sensitively. In contrast to the IGF-1
mRNA, there was threefold increase in IGFBP-1 mRNA in 18
hour furosemide-treated kidney cortices, as shown in Figures 5
and 6. There was an increase of IGFBP-1 mRNA at one hour (by
195%), but this did not reach significance. IGFBP-3 did not
increase (Figs. 5 and 6).
Discussion
As we have reported in detail [23], both IGF-1 and IGFBP-1
are located in the same nephron segments. This finding is
consistent with the notion that IGFBPs modulate the action of
IGF-1 in the rat kidney, as it has been reported to do in other
systems [22]. Immunoreactivity for the peptides was located in
PCD > OMCD> CCD, mTAL> THL, and DCT in descending
order of intensity, whereas intercalated cells in collecting ducts,
macula densa cells, glomeruli, and the cytoplasm of proximal
tubule cells were negative. The differences between our results
and those of others regarding the normal localization of IGF-1
appear to be due to the method employed. Short fixation with
freshly-made 4% formaldehyde and rapid processing provided the
best demonstration of immunoreactivity in terms of both the
preservation of morphology and signal-to-noise ratio. Overnight
immersion fixation with 4% formaldehyde reduced the staining
intensity.
Chronic furosemide treatment produced dramatic diuresis and
natriuresis associated with hypertrophy, and also an increase in
immunostainable IGF-1 and IGFBP-1, particularly in the distal
nephron segments beyond the macula densa. We could not be
certain whether or not the staining for IGF-1 and IGFBP-1 was
increased in the PCD of furosemide-treated rats, since the strong
reactivity of this segment in control rats precluded an objective
evaluation for increase attributable to the drug. However, the
immunoreactivity was relatively faint in the distal nephron seg-
ments beyond the macula densa of control rats; this permitted the
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Fig. 5. Northern blot analysis of rnRNA for IGFBP-1 and IGFBP-3. Lanes 1 and 2: furosemide-treated kidney cortices 18 hour after injection. Lanes 3
and 4: furosemide-treated kidney cortices 1 hour after injection. Lanes 5 and 6: control kidney cortices (without furosemide). f3-actin mRNA was used
as internal controls.
documentation of increased staining intensity following furo-
semide. These findings in the distal neprhon were independent of
alterations with respect to corticosteroids or vasopressin, as were
the changes of tubule mass, cell volume and basolateral mem-
brane area reported previously for furosemide treated rats [6, I•
We did not attempt to quantitate IGF-1 and IGFBP-1 in the
kidney cortex. The small size of these peptides permits their free
diffusion into the renal interstitium and access to tubular lumina
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Fig. 6. Quantitation of mRNA for IGFBP-1 (A) and IGFBP-3 (B) er-
pressed as fold increase when compared in a ratio of density of f3-a ctin
mRNA. Note that there is time-dependent increase in IGFBP-1 mRNA,
while not IGFBP-3 mRNA. Results were obtained with triplicate
experiments.
by glomerular filtration. Thus, measurement of cell associated
peptides would be confounded by a large and variable extracellu-
lar pool. Although we did not measure circulating corticosteroid
hormones, our experimental protocol was quite similar to that
employed by Kaissling and Stanton in which these hormone levels
were effectively 'clamped' at physiologically relevant levels [6, 7,
24]. Because hormonal effects secondary to diuresis were ruled
out as contributory factors, this finding has been taken to be
consistent with a role for increased sodium uptake and Na-K
ATPase activity in cellular hypertrophy. It seems possible that
IGF-1 associated with IGFBP-1 may contribute to the hypertro-
phic response by linking salt transport and the ensuing cell
hypertrophy through an unknown mechanism. That increased
sodium transport may be linked to cell hypertrophy was suggested
by Fine et a! [1]. Segal and Fine have also reported that IGF-1 can
induce proximal tubule cell hypertrophy in primary culture [30].
Although these studies are remote in context from our findings
in vivo in the distal nephron, they are supportive of a link between
salt transport related work load and cell hypertrophy. Also, they
raise the possibility of growth factors being involved in processes
that lead to cell hypertrophy.
Because IGF-1 mRNA was not increased in furosemide-treated
rats, the alterations in immunostainable IGF-1 would seem to be
due either to increased synthesis by post transcriptional mecha-
nisms or decreased breakdown of peptide. It is also possible that
IGF-1 is simply accumulated from other sources, such as the
peritubular or tubular fluids. Another intriguing mechanism to
consider involves IGFBP-1 which was colocalized and increased in
parallel with IGF-1. Small forms of IGFBP are not restricted to
circulating blood but are widely distributed in diverse tissues.
They are largely unsaturated with IGF-1 and have been shown to
enhance the biological response to IGF-1 [22]. Of interest to note
is the finding that IGFBP-1 mRNA was increased in furosemide-
treated rats without concomitant increase of mRNA for the
GH-dependent large molecular weight form of IGFBP-3. Taken
together, increased workload induced by furosemide on tubules
might stimulate the production of IGFBP-1 mRNA through yet
unknown mechanism(s), thus leading to the increased synthesis of
cell associated IGFBP-1 peptide. These cell associated IGFBPs
could trap extracellular IGF-1 by virtue of their affinity for the
peptide, increase its local concentration and cause it to be
retained in situ for a longer period.
Investigation of the mechanisms involved in the increased
expression of IGF-1 and IGFBP-1 in furosemide treated kidneys
is likely to be difficult. One complicating feature is the possible
hemodynamic effect of furosemide. It has been suggested that
furosemide increases the glomerular filtration rate, although this
remains controversial [3 1—33]. If furosemide does indeed augment
glomerular filtration, it is possible that the filtered load of IGF-1
and IGFBP-1 was increased. This could have contributed to the
increased tubular localization, although the selective localization
and increase in the distal nephron would still have to be explained.
Other confounding factors in the design of experiments to study
the phenomenon we have described are the heterogeneity of cell
populations in the nephron, the selectivity of the changes to only
a few cell types and the difficulties of measuring IGF-1 and
IGFBP-1 protein in the involved segments, free of circulating
peptides present in the filtrate and peritubular fluid. Precise
definition of the relationships between salt transport, growth
factors and cell hypertrophy may have to await the development
of appropriate models with isolated distal nephron tubules or cells
in primary culture. This field of investigation is still in a state of
infancy and little mechanistic information on the function of
IGF-1 and IGFBPs in the kidney has been garnered. For example,
although it has been recently shown that collecting duct cells and
cultured glomerular mesangial cells synthesize IGFBP [34—36],
the function of the peptide in these cell systems also remains
unknown.
In conclusion, the present experiment demonstrated that furo-
semide enhanced immunostainable IGF-1 in distal nephron seg-
ments beyond the macula densa in association with marked
tubular hypertrophy, diuresis, natriuresis, and kaliuresis. Al-
though IGF-1 mRNA was not increased by furosemide, immuno-
reactivity for IGFBP-1 (25 kDa) and IGF-1 were increased in
I
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parallel with IGFBP-1 mRNA. Because furosemide treatment in
a similar experimental protocol induced cell hypertrophy associ-
ated with increased Na uptake in the distal nephron, our results
suggest that IGF-1 and/or IGFBP-1 might contribute to hypertro-
phic responses in these nephron segments by linking functional
cellular workload to the ensuing hypertrophy.
Acknowledgments
This work was supported by NIH grant DK 17387. We thank Sue
Clayton for typing the manuscript.
Reprint requests to Shuzo Kobayashi, M.D., Department of Medicine, NTT
Izu Teishin Hospita4 750 Hirai Kannami-cho, Tagata-gun, Shizuoka, 419-01
Japan.
References
1. FINE LG: The biology of renal hypertrophy. (editorial review) Kidney
mt 29:619—634, 1985
2. HAYSLETr JP: Functional adaptation to reduction in renal mass.
Physiol Rev 59:137—164, 1979
3. HOSTETFER TH, OlsoN JR, RENNKE HG, VENKATACHALAM MA,
BRENNER BM: Hyperfiltration in remnant nephrons: A potentially
adverse response to renal ablation. Am J Physiol 241:F85—F93, 1981
4. OLSON JL, HEI'TINSTALL R: Biology of disease. Nonimmunologic
mechanisms of glomerular injury. Lab Invest 59:564—578, 1988
5. KIlL F, KUNT A, REFSUM HE: Renal sodium transport and oxygen
consumption. Am J Physiol 201:511—516, 1961
6. KAISSLING B, STANTON BA: Adaptation of distal tubule and collecting
duct to increased sodium delivery. I. Ultrastructure. Am J Physiol
255:F1256—F1268, 1988
7. STANTON BA, KAISSLING B: Adaptation of distal tubule and collect-
ing duct to increased Na delivery. II. Na and K transport. Am J
Physiol 255:F1269—F1275, 1988
8. FINE LG, BADIE-DEZFOOLY B, LOWE AG, HAMZEH A, WELLS J,
SALEHMOGHDDAM 5: Stimulation of Na!H antiport is an early event
in hypertrophy of renal proximal tubular cells. Proc NatlAcad Sci USA
82:1736—1740, 1985
9. SALEHMOGHADDAM 5, BRADLEY T, MIKHAIL N, BADIE-DEZFOOLY B,
NORD EP, TRIZNA W, KI-IEYFETS R, FINE LG: Hypertrophy of
basolateral Na-K pump activity in the proximal tubule of the remnant
kidney. Lab Invest 53:443—452, 1985
10. WEINMAN EJ, RENQUIST K, STROUP R, KASHGARIAN M, HAYSLETT JP:
Increased tubular reabsorption of sodium in compensatory renal
growth. Am J Physiol 224:565—571, 1973
11. FROESCH ER, SCHMID C, SCHWANDER J, ZAPF J: Actions of insulin-
like growth factors. Ann Rev Physiol 47:443—467, 1985
12. WADA J, ZHENG ZL, ALVARES K, KUMAR A, WALLNER E, MAKINO H,
KANWAR YS: Cloning of cDNA for the alpha subunit of mouse
insulin-like growth factor I receptor and the role of the receptor in
metanephric development. Proc Nati Acad Sci USA 90:10360—10364,
1993
13. ANDERSON G, JENNISCH E: IGF-I immunoreactivity is expressed by
regenerating renal tubular cells after ischaemic injury in the rat. Acta
Physiol Scand 132:453—457, 1988
14. D'ERCOLE Al, STILES AD, UNDERWOOD LE: Tissue concentration of
somatomedin C: Further evidence for multiple sites of synthesis and
paracrine mechanisms of action. Proc NatlAcad Sd USA 81:935—939,
1984
15. DAUGHADAY WH, ROTWEIN P: Insulin-like growth factor I and II.
Peptide, messenger ribonucleic acid and gene structures, serum, and
tissue concentrations. Endocr Rev 10:68—91, 1989
16. HAMMERMAN MR: The growth hormone-insulin-like growth factor
axis in kidney. Am J Physiol 257:F503—F514, 1989
17. HIRSCHBERG R, KOPPLE JD: Evidence that insulin-like growth factor
I increases renal plasma flow and glomerular filtration rate in fasted
rats. J C/in Invest 83:326—330, 1989
18. STILES AD, SOSENKO IRS, D'ERCOLE AJ, SMITH BT: Relation of
kidney tissue somatomedin-C/insulin-like growth factor I to post-
nephrectomy renal growth in the rat. Endocrinology 117:2397—2401,
1985
19. EL NAHAS AM, LE CARPENTIER JE, BAssErr AH, HILL DJ: Dietary
protein and insulin-like growth factor-I content following unilateral
nephrectomy. Kidney Int 36(Suppl 27):15—19, 1989
20. L'UAItA R, ROTwEIN P, BORTZ JD, HANSEN VA, SADOW JL, BErFS
CR, ROGERS SA, HAMMERMAN MR: Dual regulation of insulin-like
growth factor I expression during renal hypertrophy. Am J Physiol
257:F252—F261, 1989
21. 001 GT, HERINGTON AC: The biological and structural characteriza-
tion of specific serum binding proteins for the insulin-like growth
factors. J Endocrinol 118:7—18, 1987
22. ELGIN RG, BUSBY WH, CLEMMONS DR: An insulin-like growth factor
(IGF) binding protein enhances the biologic response to IGF-I. Proc
Nat! Acad Sci USA 84:3254—3258, 1987
23. KOBAYASHI 5, CLEMMONS DR, VENKATACHALAM MA: Colocalization
of insulin-like growth factor binding protein with insulin-like growth
factor-I. Am J Physiol 261:F22—F28, 1990
24. STANTON BA: Regulation by adrenal corticosteroids of sodium and
potassium transport in loop of Henle and distal tubule of rat kidney.
J Clin Invest 78:1612—1620, 1986
25. CHENG SWT, NORTH WG, GELLAI M: Replacement therapy with
arginine vasopressin in homozygous Brattleboro rats. The Brattleboro
rat. Ann ZVYAcad Sci 394:473—480, 1982
26. HSU SM, RAINE L, FANGER H: Use of avidin-biotin peroxidase
complex (ABC) in immunoperoxidase techniques: A comparison
between ABC and unlabelled antibody (PAP) procedures. J Histo—
chem Cytochem 29:577—580, 1981
27. BUSBY WH, KLAPPER DO, CLEMMONS DR: Purification of a 31,000
dalton insulin-like growth factor binding protein from human amni-
otic fluid. Isolation of two forms with different biologic actions. J Biol
Chem 263:14203—14210, 1988
28. CHOMCZYNSKI P, SACCHI N: Single step method of RNA isolation by
acid guanidinium thiocyanate-phenol-chloroform extraction. Anal
Biochem 162:156—159, 1987
29. ZINN K, DIMAI0 D, MANIATIS T: Identification of two distinct
regulatory regions adjacent to the human interferon gene. Cell
34:865—879, 1983
30. SEGAL R, FINE LG: Polypeptide growth factors and the kidney. Kidney
Int 36:S2—S10, 1989
31. SCHERZER P, WALD H, POPOVTZER MM: Enhanced glomerular
filtration and Na-K-ATPase with furosemide administration. Am J
Physiol 252:F910—F915, 1987
32. BURKE TJ, ROBINSON RR, Ci'p JR: Determinants of the effect of
furosemide on the proximal tubule. Kidney tnt 1:12—18, 1972
33. DUARTE CO. CHOMETY F, GIEBISCH G: Effect of amiloride, ouabain,
and furosemide on distal tubular function in the rat. Am J Physiol
221:632—639, 1971
34. ARON DC, SAADI H, ABBOUD HE: Synthesis of insulin-like growth
factor I and its binding protein by rat glomerular mesangial cells.
(abstract) Endocrinology 354:1989
35. PERFETITI RF, C0NTI FC, ELLIOT SE, STRIKER LI, STRIKER GE: Mouse
glomerular mesangial cells in culture produce insulin like growth
factor-I binding proteins. (abstract) Endocrinology 275:1988
36. ARON DC, SAAnI H, NYE CN, DOUGLAS JD: Secretion of insulin-like
growth factor I and its binding proteins by collecting duct cells. Kidney
Int 39:27—32, 1991
